U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06952517) titled 'Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea: A Phase 2 Clinical Trial' on April 23.
Brief Summary: To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Study Start Date: March 14
Study Type: INTERVENTIONAL
Condition:
Papular-pustular Rosacea
Papulopustular Rosacea (PPR)
Papulopustular Rosacea
Intervention:
DRUG: Clascoterone Cream 1%
Clascoterone 1% cream
Recruitment Status: RECRUITING
Sponsor: Narrows Institute for Biomedical Research
Published by HT Digital Content Services wit...